Neuropathological Examination is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Neuropathological examination — the systematic gross and microscopic analysis of brain tissue, typically obtained at autopsy — remains the definitive gold standard for diagnosing most neurodegenerative diseases (Dickson, 2012). Despite major advances in fluid biomarkers ([CSF[/diagnostics/csf-biomarkers, [plasma[/diagnostics/plasma-biomarkers and [neuroimaging[/diagnostics/neuroimaging including [PET[/diagnostics/pet-imaging, no combination of in vivo tests can yet match the diagnostic specificity achieved by direct visualization of pathological protein deposits, cellular changes, and regional patterns of neurodegeneration in tissue. Neuropathological examination has shaped our understanding of every major neurodegenerative disease — defining the [Amyloid-Beta[/proteins/Amyloid-Beta plaques and tau[/proteins/tau-protein tangles of [Alzheimer's disease[/diseases/alzheimers, the Lewy bodies of [Parkinson's disease[/diseases/parkinsons, the [TDP-43[/proteins/tdp-43 inclusions of [ALS[/diseases/als-[FTD[/diseases/ftd, and the prion plaques of [Creutzfeldt-Jakob disease[/diseases/creutzfeldt-jakob. It continues to reveal new pathological entities and co-pathologies that inform our understanding of neurodegeneration and validate emerging biomarkers.
The macroscopic examination reveals patterns of atrophy that suggest specific diagnoses:
| Disease | Gross Findings |
|---|---|
| [Alzheimer's disease[/diseases/alzheimers | Diffuse cortical atrophy (temporal > frontal > parietal), widened sulci, [hippocampal] atrophy, ventricular dilation |
| [FTD[/diseases/ftd | Frontal and/or anterior temporal lobe atrophy (often asymmetric); "knife-edge" gyri |
| [Parkinson's disease[/diseases/parkinsons | Pallor of [substantia nigra[/brain-regions/substantia-nigra and [locus coeruleus[/brain-regions/locus-coeruleus (loss of neuromelanin pigmentation) |
| [Huntington's disease[/mechanisms/huntington-pathway | Severe caudate nucleus and putamen ([striatum[/brain-regions/striatum atrophy; ex vacuo ventricular dilation |
| [ALS[/diseases/als | Often grossly unremarkable brain; [motor cortex[/brain-regions/motor-cortex atrophy in some cases; [spinal cord[/brain-regions/spinal-cord thinning |
| [CJD[/diseases/creutzfeldt-jakob | Cortical spongiform change; rapid brain atrophy |
| [MSA[/diseases/msa | Putaminal atrophy; cerebellar and pontine atrophy (olivopontocerebellar type) |
Standard tissue processing involves paraffin embedding, sectioning (4-8 um), and staining:
Routine stains:
Immunohistochemistry (IHC) — the cornerstone of modern neuropathological diagnosis:
| Antibody | Target | Disease Association |
|---|---|---|
| Anti-[amyloid-beta[/entities/amyloid-beta (4G8, 6E10) | [Amyloid-Beta[/proteins/Amyloid-Beta plaques | [Alzheimer's disease[/diseases/alzheimers, [CAA] |
| Anti-phospho-tau] (AT8, PHF-1) | [Hyperphosphorylated tau] | AD, [PSP[/diseases/psp, [CBD[/diseases/corticobasal-degeneration, [FTLD-tau] |
| Anti-[alpha-synuclein[/proteins/alpha-synuclein | [alpha-synuclein[/proteins/alpha-synuclein aggregates | [PD], [DLB], [MSA[/diseases/msa |
| Anti-[TDP-43[/entities/tdp-43 (phospho) | [TDP-43[/proteins/tdp-43 inclusions | [ALS[/diseases/als, [FTLD-TDP], [LATE[/diseases/late |
| Anti-FUS | [FUS[/proteins/fus-protein inclusions | FTLD-FUS, ALS-FUS |
| Anti-p62/SQSTM1 | [p62[/proteins/p62-sqstm1 inclusions | Pan-neurodegenerative marker |
| Anti-ubiquitin | Ubiquitinated inclusions | Non-specific; identifies protein aggregates |
| Anti-prion protein | [Prion protein[/proteins/prion-protein deposits | [CJD[/diseases/creutzfeldt-jakob, [GSS[/genes/gss |
| Anti-[huntingtin[/proteins/huntingtin (polyQ) | [Huntingtin[/proteins/huntingtin aggregates | [Huntington's disease[/mechanisms/huntington-pathway |
| [GFAP[/entities/glial-fibrillary-acidic-protein | Reactive [astrocytes[/cell-types/astrocytes | Gliosis marker (non-specific) |
| Iba1 | [microglia[/cell-types/microglia/cell-types/microglia | [neuroinflammation[/mechanisms/neuroinflammation marker |
Standardized staging systems enable systematic classification of disease severity:
The NIA-AA neuropathological criteria assess three features using the "ABC" score (Montine et al., 2012):
The combination of ABC scores yields a composite neuropathological diagnosis: Not AD, Low, Intermediate, or High AD neuropathologic change.
The Braak staging system for Lewy body pathology describes caudal-to-rostral progression (Braak et al., 2003):
FTLD is classified by the predominant protein pathology (Mackenzie et al., 2010):
[TDP-43[/proteins/tdp-43 pathology in ALS follows a four-stage spread pattern from the [motor cortex[/brain-regions/motor-cortex and [spinal cord[/brain-regions/spinal-cord motor [neurons[/entities/neurons (stage 1) through [prefrontal cortex[/brain-regions/prefrontal-cortex and brainstem reticular formation (stage 2-3) to [hippocampus[/brain-regions/hippocampus and temporal [cortex[/brain-regions/cortex (stage 4) (Brettschneider et al., 2013).
One of the most important contributions of neuropathological examination is revealing the high prevalence of co-occurring pathologies:
These findings explain why single-target therapies (e.g., anti-amyloid) may have limited clinical efficacy and underscore the importance of addressing multiple pathological processes.
Whole slide imaging (WSI) and computational pathology are transforming neuropathological practice:
Neuropathological examination enables critical clinicopathological correlations:
Major brain bank networks support neuropathological research:
The study of Neuropathological Examination has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.